Summary The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2, as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with <4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
Malignant mesothelioma is almost invariably a lethal tumour of the pleura or the peritoneum (ratio 2.5: 1); it is linked to asbestos exposure and its incidence is steadily increasing (De Klerk and Armstrong, 1992) . Diagnosis requires large biopsy samples and exclusion of metastatic tumours . Computed tomography (CT) is essential for staging the extent of disease. In most studies, Butchart's modified staging system is used, based on surgical and pathological findings; however, recently a TNM classification has been approved and a conversion table from Butchart's to the UICC staging system proposed (Langlois and Henderson, 1992; UICC, 1992; Boutin et al., 1993) .
Survival of untreated patients is poor with a median of less than 12 months, but with sporadic long-term survivors. Prognosis is influenced by histological subtype, performance score and disease extent at diagnosis (Boutin et al., 1993; Pisani, 1988; Calavrezos et al., 1988; van Meerbeeck, 1994) . Surgery and radiotherapy have little impact on survival in malignant pleural mesothelioma (Rush et al., 1991; Ball and Cruickshank, 1990) . Numerous chemotherapeutic agents have been tested but results have generally been disappointing. Literature reviews indicate some activity for anthracyclines alone or in combination chemotherapy. Doxorubicin is considered the single agent with the highest activity, ranging from 14% to 40%, resulting in a median survival of 14 months (Kraruf-Hansen and Hansen, 1991; Musk et al., 1992) .
The Lung Cancer Cooperative Group (LCCG) of the EORTC has conducted sequential phase II studies in malignant pleural mesothelioma with mitoxantrone, epirubicin and etoposide (van Breukelen et al., 1991; Mattson et al., 1992; PE Postmus, unpublished results) . None of these drugs obtained more than a 15% response rate.
Paclitaxel is a new drug with anti-tumour activity in several tumour types, such as ovarian cancer, breast cancer and non-small-cell lung cancer (Rowinsky and Donehower, 1995) . The mechanisms of action and resistance, toxicity and clinical pharmacology have been extensively reviewed (Rowinsky et al., 1993 WHO criteria (EORTC, 1994) . The use of CT scans was mandatory for evaluation of intrathoracic target lesions. Toxicity was scored according to the common toxicity criteria of the NCI completed by the NCIC (EORTC, 1994) . This study was planned according to the two-stage Gehan design aiming at rejecting a drug with a response rate below 20%, and evaluating the response rate with a standard error inferior to 10% (Simon, 1989) . The Kaplan-Meier method was used to estimate overall survival and duration of stabilisation (Kaplan and Meier, 1958 (van Meerbeeck, 1994) . For the majority of patients systemic therapy can be considered at some time. In a review of published series, only 11% of single-agent chemotherapy studies and 9% of combination chemotherapy studies were stated to give sufficiently conclusive data regarding the observed activity (Kraruf-Hansen and Hansen, 1991). The majority of the pooled results, however, were inconclusive, as most studies enrolled only a few patients and the evaluation procedures were not accurate. Because of the inefficacy of currently available drugs, most authors feel that clinical studies in malignant mesothelioma should focus on phase II trials with new drugs (Vogelsang, 1992; KrarufHansen, 1994) .
One of the greatest problems in the interpretation of the efficacy of a treatment in this disease is the adequate evaluation of response. In many of the older studies, this was done on conventional chest films. Only sequential use of CT scans or magnetic resonance imaging (MRI) may provide useful information.
In this study, no therapeutic activity of paclitaxel against mesothelioma could be observed at a dosage and schedule that are commonly employed in untreated patients. The (Vogelsang et al., 1994) . The question arises whether this modest activity is due to the higher dose, to the 24 h infusion or simply to differences in patients' characteristics. In refractory ovarian cancer it was observed that 24 h infusion produced more myelosuppression but did not yield a higher response. The maximum tolerated dose (MTD) of pacitaxel recommended for phase H studies, when administered as a 3 h infusion, is 210 mg m-2, myelosuppression being dose limiting (Schiller et al., 1994) . The MTD of paclitaxel administration with CSF support is 250 mg m-2, neurotoxicity being dose limiting (Schiller et al., 1994) . The toxicity findings of the present study are similar to other studies employing 3 h infusions of pacitaxel. Interestingly, in this study no severe hypersensitivity reaction or cardiac disturbances occurred.
Cytoplasmic immunoreactivity for P-170 glycoprotein has been described in the majority of mesothelioma specimens in one study (Ramael et al., 1992) . P-glycoprotein (P-gp) functions as a drug efflux pump and is associated with the multidrug-resistance phenotype. Whether this mechanism of drug resistance contributes to resistance to paclitaxel in malignant mesothelioma remains speculative. Paclitaxel is, however, a substrate of P-glycoprotein and overexpression of P-gp has been shown to be responsible for resistance to paclitaxel in mammalian cell lines (Gupta, 1993) .
In conclusion, pacitaxel was well tolerated at this dose and schedule in patients with chemotherapy-untreated malignant pleural mesothelioma. The absence of major objective responses does not warrant further testing of pacitaxel in this disease.
